BioCentury
ARTICLE | Company News

MedImmune to acquire Definiens

November 5, 2014 2:46 AM UTC

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire Definiens AG (Munich, Germany) for $150 million up front plus potential milestones. MedImmune spokesperson Tracy Rossin said the company will use Definiens' Cognition Network Technology to discover biomarkers associated with MedImmune's immuno-oncology discovery programs and AstraZeneca's small molecule portfolio.

The deal is expected to close this quarter. ...